Suchergebnisse - "Risk category"

PubPharm (213)

1

Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes mellitus

enthalten in: Clinica chimica acta; international journal of clinical chemistry | 2024

von Chang, L. | Chang, T. | Chu, C. | +2

2

Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters

enthalten in: European urology oncology | 2024

von Mazzone, E. | Gandaglia, G. | Robesti, D. | +28

3

Early-onset neonatal sepsis : Effectiveness of classification based on ante- and intrapartum risk factors and clinical monitoring

enthalten in: Journal of gynecology obstetrics and human reproduction | 2024

von Dalut, L. | Brunhes, A. | Cambier, S. | +2

4

Usefulness of PREDIC3T Case Type Risk Category in the CRISP Registry

enthalten in: The American journal of cardiology | 2024

von Kobayashi, D. | Amin, E. | Morgan, G. | +4

5

The relationship between maternal anemia and electronic fetal monitoring patterns

enthalten in: American journal of obstetrics and gynecology | 2023

von Beermann, S. | Watkins, V. | Frolova, A. | +2

6

The TG/HDL-c Lipid Ratio as a Cardiovascular Risk Marker in a Mexican Urban Middle-Class Population : Do We Need a Risk Score Tailored for Mexicans?

enthalten in: Journal of clinical medicine | 2023

von Martínez-Marroquín, Y. | Meaney, A. | Samaniego-Méndez, V. | +4

7

A study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS), or Chronic Myelomonocytic Leukemia-2 (CMML-2) : A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

enthalten in: WHO International Clinical Trials Registry Platform | 2023

8

A study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS), or Chronic Myelomonocytic Leukemia-2 (CMML-2) : A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

enthalten in: WHO International Clinical Trials Registry Platform | 2023

9

Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype

enthalten in: Cancers | 2023

von Blanca, A. | Lopez-Beltran, A. | Lopez-Porcheron, K. | +6

10

Hyperuricemia Predicts the Progression of Type 2 Diabetic Kidney Disease in Chinese Patients

enthalten in: Diabetes therapy : research, treatment and education of diabetes and related disorders | 2023

von Zhu, L. | Wang, X. | Sun, J. | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[22]